PFE - Virios Therapeutics Seeks IPO For Fibromyalgia Pain Treatment
Quick Take
Virios Therapeutics (VIRI) has filed to raise $34.5 million in an IPO of its common stock, according to an S-1 registration statement.
The company is developing a drug treatment for fibromyalgia, a nerve pain condition.
VIRI has generated interesting early stage efficacy results in reducing viral replication related to fibromyalgia pain.
I’ll provide a final opinion when we learn more details about the IPO.
Company & Technology
Alpharetta, Georgia-based Virios was founded to develop its IMC-1 candidate designed to inhibit HSV-1 (Herpes Simplex Virus) activation which may play a role